Phase II Study of Nimotuzumab, a Humanized Monoclonal Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, in Patients with Locally Advanced or Metastatic Pancreatic Cancer
Investigational New Drugs（2010）
Key words
Pancreatic cancer,Nimotuzumab,EGFR antibody,Clinical trial,Advanced disease
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined